A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma : A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible - CARTITUDE-6
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
WHO International Clinical Trials Registry Platform - (2023) vom: 09. Jan. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 05-08-2022, Last updated: 2023-01-13 |
|---|
| ICTRP ID: |
EUCTR2021-003284-10-NL |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CTG008889007 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG008889007 | ||
| 003 | DE-627 | ||
| 005 | 20230425173103.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230113s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG008889007 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)EUCTR2021-003284-10-NL | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)EMN28/68284528MMY3005 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)NCT05257083 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)2021-003284-10-SE | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma |b A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible - CARTITUDE-6 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 05-08-2022, Last updated: 2023-01-13 | ||
| 650 | 4 | |a Medical Condition: Multiple Myeloma MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04] | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Phase: Phase 3 | |
| 650 | 4 | |a Recruitment Status: Authorised-recruitment may be ongoing or finished | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t WHO International Clinical Trials Registry Platform |g (2023) vom: 09. Jan. |
| 773 | 1 | 8 | |g year:2023 |g day:09 |g month:01 |
| 856 | 4 | 0 | |u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-003284-10 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 09 |c 01 | ||